SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥146.69+CN¥3.80 (+2.66%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.62% below the high.
Loading market information…
HKSE · 6622.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:57 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Zhaoke Ophthalmology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Zhaoke Ophthalmology Limited’s next earnings report is currently expected on Mar 29, 2027, with estimated earnings per share of -HK$0.46. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Zhaoke Ophthalmology Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company is advancing a range of medications designed for various ocular conditions, impacting both the anterior and posterior segments of the eye, such as dry eye disease, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. It was previously known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was established in 2017 and operates from its headquarters in Guangzhou, People's Republic of China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 |
|---|
| Mar 27, 2024 |
| -HK$0.31+45.1% vs estimate |
| HK$8.19M-27.51% vs estimate |
| Q2 2023 | Aug 23, 2023 | -HK$0.46-4.88% vs estimate | HK$12.22M+371.79% vs estimate |
|---|
| Q4 2022 | Mar 27, 2023 | -HK$0.51-12.5% vs estimate | HK$0.00-100.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥146.69+CN¥3.80 (+2.66%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.62% below the high.
CN¥49.14+CN¥0.52 (+1.07%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.03% below the high.
HK$51.75+HK$1.10 (+2.17%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 35.64% below the high.
CN¥181.56+CN¥2.56 (+1.43%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 19.38% below the high.
HK$33.16+HK$0.08 (+0.24%)
Hansoh Pharmaceutical Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 24.83% below the high.
HK$45.50+HK$0.44 (+0.98%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.07% below the high.
HK$4.79+HK$0.18 (+3.8%)
Ocumension Therapeutics’s quoted price sits in the lower half of its reported 52-week range, 46.48% below the high.
HK$1.19+HK$0.03 (+2.15%)
Cloudbreak Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.58% below the high.
